Updates are available Correction dated 2021-02-16
Click to view Correction: https://doi.org/10.1186/s13063-021-05057-3
-
Authors
Odgis, Jacqueline A.
Gallagher, Katie M.
Suckiel, Sabrina A.
Donohue, Katherine E.
Ramos, Michelle A.
Kelly, Nicole R.
Bertier, Gabrielle
Blackburn, Christina
Brown, Kaitlyn
Fielding, Lena
Lopez, Jessenia
Aguiniga, Karla Lopez
Maria, Estefany
Rodriguez, Jessica E.
Sebastin, Monisha
Teitelman, Nehama
Watnick, Dana
Yelton, Nicole M.
Abhyankar, Avinash
Abul-Husn, Noura S.
Baum, Aaron
Bauman, Laurie J.
Beal, Jules C.
Bloom, Toby
Cunningham-Rundles, Charlotte
Diaz, George A.
Dolan, Siobhan
Ferket, Bart S.
Jobanputra, Vaidehi
Kovatch, Patricia
McDonald, Thomas V.
McGoldrick, Patricia E.
Rhodes, Rosamond
Rinke, Michael L.
Robinson, Mimsie
Rubinstein, Arye
Shulman, Lisa H.
Stolte, Christian
Wolf, Steven M.
Yozawitz, Elissa
Zinberg, Randi E.
Greally, John M.
Gelb, Bruce D.
Horowitz, Carol R.
Wasserstein, Melissa P.
Kenny, Eimear E. https://orcid.org/0000-0001-9198-759X
-
Funding
Funding for this research was provided by:
National Human Genome Research Institute (U01HG009610)
- License Information
-
More Information
Article History
Received: 23 August 2020
Accepted: 8 December 2020
First Online: 14 January 2021
Change Date: 16 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13063-021-05057-3
Ethics approval and consent to participate
: The Institutional Review Boards of Icahn School of Medicine at Mount Sinai and Albert Einstein College of Medicine approved this study protocol. Written, informed consent to participate will be obtained from all participants.
: A model consent form will be made available upon request.
: EEK has received speaker honorariums from Regeneron and Illumina. NSAH was previously employed by Regeneron Pharmaceuticals and has received a speaker honorarium from Genentech. AB has received consulting fees from the American Board of Family Medicine outside the submitted work. JCB has received an honorarium from LivaNova. AR has received funding by TAKEDA for two clinical trials: HYQVIA in Pediatric CVID Patients (2018-2021) and SCIG Treatment for Chronic Inflammatory Demyelinating Polyneuropathy. RZ has received consulting fees from Sema4 outside the submitted work. All other authors declare they have no competing interest.
